UICC works in partnership with corporations, members and foundations to improve its ability to support the cancer community and drive action on a global scale.
There are currently about 14 million new cancer cases diagnosed each year globally, and 8.2 million cancer deaths - more than HIV/AIDS, malaria, and tuberculosis combined. Over 50% of these deaths occur in low- and middle-income countries and the number of new cases is expected to rise over the next two decades unless we make significant progress to reverse this trend.
Fostering inclusive partnerships represents the foundation of how UICC operates and delivers impact. This is why we work hand in hand with a variety of stakeholders to drive transformational changes and make progress in the fight against cancer.
Our portfolio of partnerships includes cancer organisations, foundations, and private sector companies with which we have developed long-term commitments based on shared ambitions.
Together we aim to make a significant difference on the ground through our global leadership in three priority areas: convening, capacity building and advocacy.
“The ambition of UICC to have cancer treatment solutions in all cities with a population of over 1 million people by 2025 is truly visionary. This, coupled with their track record of delivering with excellence, makes UPMC proud to be involved as a partner. Through initiatives such as these, we are on our way to reach the global target of reducing cancer’s burden by 25% by 2025.”
“Joining forces with UICC through the SPARC grants initiative helps bring the cancer community one step closer to the day when metastatic breast cancer patients around the world have access to the care and support they need, regardless of their location or socio- economic status. Our partnership with UICC supports our commitment to projects that can greatly impact the lives of women living with a metastatic breast cancer diagnosis.”
The American Cancer Society is a global grassroots force of 2.5 million volunteers saving lives in every community. As the largest voluntary health organization, the Society’s efforts have contributed to a 25 percent decline in the cancer death rate in the U.S. since 1991, driven by less smoking, better treatments, and earlier detection. The American Cancer Society is finding cures as the United States largest private, not-for-profit investor in cancer research, ensuring people facing cancer have the help they need and continuing the fight for access to quality health care, lifesaving screenings and more. The Society’s global outreach efforts promote prevention and healthy living, reduce pain and suffering from cancer and help support cancer organizations in low and middle income countries, and provide a platform for advocacy and patient support in nearly 30 countries.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
The Astellas Group aims to become a R&D-driven global pharmaceutical company contributing to people’s health. Astellas’s business philosophy has three elements — raison d'être, mission and beliefs. This business philosophy expresses the company’s aim to contribute to the health of people around the world through the provision of highly effective and trustworthy pharmaceuticals, while continuously increasing the Company's enterprise value.
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
CDC works 24/7 to protect America from health, safety and security threats, both foreign and in the U.S. Whether diseases start at home or abroad, are chronic or acute, curable or preventable, human error or deliberate attack, CDC fights disease and supports communities and citizens to do the same. CDC increases the health security of our nation. As the nation’s health protection agency, CDC saves lives and protects people from health threats. To accomplish our mission, CDC conducts critical science and provides health information that protects our nation against expensive and dangerous health threats, and responds when these arise.
The German Cancer Society (DKG) is the largest scientific and specialist oncology company in Germany with headquarters in Berlin. They are engaged in cancer care on the basis of evidence-based medicine, interdisciplinary and consequent quality standards. In total, DKG has about 7600 members, organised in 24 working groups, 16 regional cancer societies and 34 sponsors from research-based pharmaceutical industries, scientific publishers and health insurances. Since cancers need to be cross-treated and researched, their members are not only medical doctors of all sections, but also basic researchers, medical technical assistants, nurses, psychologists and other professionals who work on cancer.
DKG specialises in certification of oncological care institutions, development of clinical practice guidelines, coordination of guidelines in the framework of the German Guideline Program of Oncology (GGPO), development and transfer of oncological knowledge, and improvement of information given to patients.
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Their advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology.
Their treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm
An umbrella foundation associated with the bank Lombard Odier and a registered charity, Fondation Philanthropia has been helping its donors bring their philanthropic initiatives to fruition in all areas of social responsibility since 2008. It provides philanthropic expertise and support to those who wish to develop a philanthropic project in line with their background, desires and ambitions. The Foundation offers its donors a legal, financial and philanthropic framework for made-to-measure projects.
The Foundation now operates more than 20 personal funds and has received over 115 million Swiss francs in donations, of which over a third has already been distributed or committed. Its donors have been highly committed to the fight against cancer, with over 15 million spent on the cause.
Created in 2010 by Sanofi Group to fortify its international solidarity and make its commitment clearer to all stakeholders, the Sanofi Espoir Foundation aims to reduce healthcare inequalities and poverty among the world’s poorest populations. Its action lines are focused on three priority areas: fighting childhood cancer in low-income countries, Improving maternal and newborn healthcare and delivering access to care for the most vulnerable social groups, particularly in France. The Sanofi Espoir Foundation naturally responds to humanitarian emergencies, but focuses primarily on long term partnerships to act on such recurrent issues as education and prevention, training and access to care.
Icon Group is a leading provider of cancer care across Australasia. Icon believes in bringing the best cancer treatment possible, to as many people as possible, as close to home as possible. They do this through leveraging the latest technology, collaborating with like-minded partners and investing in outstanding people.
Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. They embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Their approximately 126,400 employees at more than 230 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
For 130 years, Johnson & Johnson has been committed to improving the health of individuals, families and communities around the world, including the most vulnerable populations. Today, their vibrant, entrepreneurial and committed employees bring business acumen and their collaborative spirit to help solve some of the most complex global health problems. By harnessing their collective breadth and scale, and their employees’ passion and purpose, Johnson & Johnson strives to advance health care and positively impact the lives of all people.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the “Merck” name and brand except in the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.
The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide.
The Swiss Cancer League is a national, charitable, private organisation, founded in 1910. It is the Berne-based headquarter of an association of 19 regional cancer leagues. The Swiss Cancer League covers all aspects of cancer, with the aim of ensuring that fewer people develop cancer, fewer people suffer and die from the consequences of cancer and more people can be treated successfully. The organisation supports innovative cancer research projects, increases public awareness of prevention measures and is committed to early diagnosis and treatment. One of its first concerns is to ensure high-quality advice and psychological support for all cancer patients and survivors and their caretakers. The Swiss Cancer League also supports other cancer control organisations in low income countries.
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.
The Japan National Committee for UICC is a group of Japanese organisations that are members of the Union for International Cancer Control (UICC), gathered to support the UICC to strive to realise the World Cancer Declaration. Currently UICC-Japan is composed of 29 full Japanese UICC members, including major cancer specialists in Japan, cancer centres, research institutes, research funds, hospitals and cancer associations.
UPMC is a global academic medical center headquartered in Pittsburgh, Pennsylvania, United States and it is ranked No. 12 in the U.S. News & World Report Honor Roll of America’s Best Hospitals. UPMC has many clinical and research centers of excellence, including UPMC CancerCenter which is an NCI Designated Comprehensive Cancer Center. In partnership with the University of Pittsburgh Cancer Institute, it maintains rigorous standards in clinical and research quality, consistency, and outcomes at more than 50 outpatient cancer centers. With years of experience, UPMC is helping to develop new models of accountable, cost-efficient, and patient-centered care.
For nearly two decades, UPMC has shared its expertise with public and private partners spanning three continents in cancer center projects including operations management, quality and safety, training, clinical pathways, clinical research, facility and construction management and program design. Through projects in countries such as Italy, Singapore, China, Colombia, and Ireland, UPMC’s collaborations support the transformation of health care so that patients receive the best-possible cancer care, close to home.
Varian Medical Systems’ mission is to focus energy on saving lives. To meet this challenge, they equip the world with new tools for fighting cancer. Since the 1950s they have been producing tools that harness the power of X-ray energy to benefit humankind. Varian’s history is one of pioneering developments in the fields of radiotherapy, radiosurgery, X-ray tube technology, digital image detectors, cargo screening, and non-destructive testing. Today, they have a robust product portfolio and long-standing relationships with many of the world’s leading clinicians. As Varian continues to grow, their staff of over 6,500 people in 70 sales and support offices around the globe is developing innovative, cost-effective solutions that help make the world a healthier place.
World Cancer Research Fund International is the world’s leading authority on cancer prevention research related to diet, weight and physical activity. Their vision is to live in a world where no one develops a preventable cancer. On behalf of the cancer prevention charities in the World Cancer Research Fund network, WCRF commissions research from leading institutions around the world into the effects of diet, nutrition, body fatness, physical activity on cancer and cancer survival. This research aims to fill the current gaps in scientific knowledge.